Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, April 15, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that on April 14, 2025, non-qualified stock option awards to purchase an aggregate of 35,040 shares of its common stock were granted to one new employee. The stock options were granted as inducements material to the new employee becoming an employee of Cardiff Oncology in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $2.79 per share, which is equal to the closing price of Cardiff Oncology's common stock on April 14, 2025. Each option will vest over a 4-year period, with 25% of the shares vesting upon the 1-year anniversary of the date of grant and the remaining shares vesting monthly over the following 36-months, subject to the employee's continued employment with Cardiff Oncology on such vesting dates.

About Cardiff Oncology, Inc.

Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard of care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC), as well as in ongoing and planned investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com. 

Cardiff Oncology Contact:
James Levine
Chief Financial Officer
858-952-7670
[email protected] 

Investor Contact:
Kiki Patel, PharmD
Gilmartin Group
332-895-3225
[email protected] 

Media Contact:
Michael Laurer
Taft Communications
732-233-4881
[email protected]

You May Also Be Interested In

• Pace Center for Girls Receives $60,000 Grant from State Farm to Advance Career and College Preparation for Girls
• DNB Financial Group Launches New AI Trade Alerts, Earning High Praise from UK Analysts for Reliability and Speed
• Brera Holdings PLC (NASDAQ: BREA) Partners with ACF Fiorentina and Brera Holdings Board Advisor Giuseppe Rossi for ‘Pepito Day;’ Continues to Cement Its Dedication to Promoting Grassroots to Serie